Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Bezlotoxumab safely prevents recurrent Clostridioides difficile infection

09 Jan 2021

Bezlotoxumab is both safe and effective for the prevention of recurrent Clostridioides difficile infection (rCDI), results of a meta-analysis have shown. Moreover, bezlotoxumab may be a good therapeutic option for severe rather than mild CDI.

“CDI is one of the most common healthcare-associated infections,” the investigators said. “To reduce the rCDI, monoclonal antibodies against C. difficile toxin A (actoxumab) and toxin B (bezlotoxumab) were developed.”

A systematic review and meta-analysis was performed to assess their efficacy and safety. The investigators searched an electronic database for relevant randomized controlled trials (RCTs) assessing bezlotoxumab and/or actoxumab. Outcomes measured were the rate of rCDI and adverse events including cardiovascular and gastrointestinal events.

Four RCTs comparing antitoxin antibodies (n=1,916) with placebo (n=889) were included in the meta-analysis. Bezlotoxumab plus actoxumab significantly reduced rCDI (risk ratio [RR], 0.54, 95 percent confidence interval [CI], 0.41–0.70; p<0.001), as did bezlotoxumab monotherapy (RR, 0.62, 95 percent CI, 0.51–0.76; p<0.001), compared with placebo.

In subgroup analysis, bezlotoxumab plus actoxumab significantly prevented rCDI in patients with high-risk features, such as inpatients, those who received vancomycin treatment, and those with the BI/NAP/027 strain.

In terms of safety, no difference was noted in cardiovascular and gastrointestinal events, as well as all-cause mortality, between patients treated with bezlotoxumab and placebo.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.